cannabis-2152604_960_720

Synthetic, non-intoxicating CBD analogue treats seizures in rats

pharmafile | May 31, 2019 | News story | Medical Communications CBD, H2CBD, cannabidiol, medicinal cannabis, pharma 

A synthetic, non-intoxicating cannabidiol (CBD)-analogue is effective at treating seizures in rats, according to researchers at the University of California, Davis.

The molecule, 8,9-Dihydrocannabidiol (H2CBD) is a synthetic molecule which is structurally similar to the CBD. Mascal’s lab developed H2CBD from commercially available chemicals.

The UC Davis researchers tested H2CBD against CBD, in rats with induced seizures. Both drugs were found to be equally effective in treating seizures in rats.

Advertisement

“It’s a much safer drug than CBD, with no abuse potential and doesn’t require the cultivation of hemp,” said Mark Mascal, professor in the UC Davis Department of Chemistry.

Mascal is now working with colleagues to carry out further clinical trials. The teams findings were published in the journal Scientific Reports.

Louis Goss

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content